Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
COMPASS Pathways Plc - American Depository Shares
(NQ:
CMPS
)
7.650
+0.170 (+2.27%)
Streaming Delayed Price
Updated: 4:00 PM EDT, May 26, 2023
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
178,761
Open
7.680
Bid (Size)
7.500 (3)
Ask (Size)
7.820 (1)
Prev. Close
7.480
Today's Range
7.550 - 7.810
52wk Range
6.970 - 21.50
Shares Outstanding
N/A
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Trial Gives Cancer Patients 18 Months Of Robust Benefits After One Psilocybin Session
May 26, 2023
Positive long-term follow-up data from Sunstone Therapies’ investigator-initiated Phase 2 study assessing COMPASS Pathways’ (NASDAQ: CMPS) synthetic psilocybin COMP360 paired with psychological support...
Via
Benzinga
Link Between Cancer And Psilocybin: Research On This Palliative Promise
May 22, 2023
The use of psychedelic-assisted therapy to treat cancer-related conditions has come a long way.
Via
Benzinga
Performance
YTD
-0.91%
-0.91%
1 Month
-4.61%
-4.61%
3 Month
-9.14%
-9.14%
6 Month
-18.96%
-18.96%
1 Year
-15.84%
-15.84%
More News
Read More
Psyched: $20M Research Fund, LSD Microdosing For Cancer, MEAI Enters Clinical Stage, Reform Update & More
May 15, 2023
Via
Benzinga
Expert Ratings for Compass Pathways
May 11, 2023
Via
Benzinga
COMPASS Pathways Reports Q1 2023: Financials, Commercial Groundwork And Ongoing Phase 3 Trials
May 11, 2023
Via
Benzinga
Compass Pathways: Q1 Earnings Insights
May 11, 2023
Via
Benzinga
Earnings Preview: Compass Pathways
May 10, 2023
Via
Benzinga
Atai Life Sciences Q1 2023 Results, Pipeline Update On DMT And Psilocybin Clinical Trials
May 11, 2023
Via
Benzinga
Compass Pathways Plc (CMPS) Q1 2023 Earnings Call Transcript
May 11, 2023
Via
The Motley Fool
COMPASS Pathways Announces First Quarter 2023 Financial Results and Business Highlights
May 11, 2023
From
COMPASS Pathways
Via
GlobeNewswire
Psyched: Psychedelics Reimbursement, Amanita Muscaria Boom, $53M Material Breach Lawsuit & More
May 08, 2023
Via
Benzinga
This Regulatory Change Means Psychedelic Stocks Are One Step Closer to Being a Buy. Here's Why
May 06, 2023
Via
The Motley Fool
EXCLUSIVE: AMA Moves Toward Psychedelic Therapy Reimbursement, Filing A Gap In Regulations
May 02, 2023
Via
Benzinga
American Medical Association to Issue First New Code for Psychedelic Therapies
May 02, 2023
From
COMPASS Pathways
Via
GlobeNewswire
April Psychedelic Drug Stocks Recap: The Ups And Downs
April 30, 2023
Via
Talk Markets
Seelos Therapeutics, Compass Pathways Among Top Psychedelic Movers Of Today
April 21, 2023
Via
Benzinga
Seelos Therapeutics, ATAI Life Sciences Among Top Psychedelic Movers Of Today
April 20, 2023
Via
Benzinga
After Falling 60% in 1 Year, Is Atai Life Sciences Stock Still a Buy?
April 20, 2023
Via
The Motley Fool
Cybin, Mind Medicine Among Top Psychedelic Movers Of Today
April 19, 2023
Via
Benzinga
Psychedelic Stock Gainers And Losers From April 18, 2023
April 18, 2023
Via
Benzinga
Psychedelic Stock Gainers And Losers From April 17, 2023
April 17, 2023
Via
Benzinga
5 Short Squeeze Stocks To Watch: Getty Images, PaxMedica, A Mental Health Care Company And More
April 17, 2023
Via
Benzinga
Psilocybin Therapy Continues To Show Positive Outcomes For Cancer And Major Depression Disorder
April 14, 2023
Via
Benzinga
ATAI Life Sciences, Seelos Therapeutics Among Top Psychedelic Movers Of Today
April 14, 2023
Via
Benzinga
Psychedelic Stock Gainers And Losers From April 13, 2023
April 13, 2023
Via
Benzinga
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.